Clinical Trial Detail

NCT ID NCT03023423
Title A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Daratumumab

Atezolizumab

Age Groups: adult senior

No variant requirements are available.